Home Stock UK’s CMA may accept Synopsys/Ansys deal remedies

UK’s CMA may accept Synopsys/Ansys deal remedies

by
0 comment

Investing.com — The UK’s Competition and Markets Authority (CMA) said it may accept the remedies offered by Synopsys (NASDAQ:SNPS) and Ansys (NASDAQ:ANSS). The agency now has until until March 5, 2025 to make an official decision. The undertakings, offered by both companies at the end of last year on December 31, include the divestment of certain product lines.

Specifically, Ansys has proposed to divest its product for power consumption analysis of digital chips. On the other hand, Synopsys has offered to divest its Optical Solutions Group. The CMA has stated that there are reasonable grounds to believe that these undertakings might be accepted.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

You Might Also Like
  • Jefferies: ‘Are we near the rebirth of new nukes?’
  • Mutual fund and ETFs post-election inflows similar to 2016: Goldman
  • Nippon Life to buy Resolution Life for $8.2 billion, Nikkei says
  • L’Oreal acquires South Korea’s Dr.G in skincare deal with Migros

You may also like